Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
Nov 4, 2026, 14:12

Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery

Jean-Jacques Kiladjian, Head of Clinical Research Department of Inserm, Professor of Medicine at the University of Paris Cité, President of the FIM, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published JCI, adding:

“From clinical observation of unusual aggressive skin secondary cancers in patients with myelofibrosis treated with JAK inhibitors to the basic lab, a beautiful example of the continuum of medical research.

Kudos to the team, and great collaboration with the dermatology department, pharmacology and pharmacovigilance units.”

Title: JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase–mediated alternative MAPK pathway activation

Authors: Hélène Pasquer, Antoine Forget, Maxime Battistella, Raphael Marie, Léa Provent, Barouyr Baroudjian, Emmanuelle Latour, Cécile Culeux, Blandine Roux, Khansa Saadallah, Amandine Gouverneur, Maxime Demourgues, Fanélie Jouenne, Jérôme Lambert, Bérangère Lombard, Damarys Loew, Sophie Tartare-Deckert, Lionel Adès, Emmanuel Raffoux, Bruno Cassinat, Juliette Soret-Dulphy, Pernelle Noize, Samia Mourah, Camille Lobry, Jean-Jacques Kiladjian, Alexandre Puissant, Céleste Lebbé, Lina Benajiba

Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory DiscoveryStay updated with Hemostasis Today.